FDA Choice For Tobacco Chief Suggests Bigger Role For Cessation Programs
This article was originally published in The Tan Sheet
Executive Summary
FDA's pick of Lawrence Deyton as the first director of the Center for Tobacco Products reveals smoking cessation may be a higher priority for the center than previously expected
You may also be interested in...
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval